Downregulation of hepatoma-derived growth factor suppresses the malignant phenotype of U87 human glioma cells

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 62-68

  Zhang, Aixia ^a   Long, Weiguo ^b   Guo, Ze ^a   Guo, Zhenying ^a   Cao, Brian B ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Glioma; Hepatoma derived growth factor; In vitro invasion; Migration

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR; LIPOFECTAMINE; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL ACTIVITY; CELL INVASION; CELL MIGRATION; CELL STRAIN U87; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; GLIOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHENOTYPE; RNA INTERFERENCE; TUMOR BURDEN;

EID: 84861540111     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1768     Document Type: Article

References (33)

1. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
2. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193, 2010.
3. Huang TT, Sarkaria SM, Cloughesy TF and Mischel PS: Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 6: 500-512, 2009.
4. Nakamura H, Kambe H, Egawa T, et al: Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 183: 273-284, 1989. (Pubitemid 19219222)
5. Everett AD and Bushweller J: Hepatoma derived growth factor is a nuclear targeted mitogen. Curr Drug Targets 4: 367-371, 2003. (Pubitemid 36758316)
6. Abouzied MM, Baader SL, Dietz F, Kappler J, Gieselmann V and Franken S: Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity. Biochem J 378: 169-176, 2004. (Pubitemid 38299554)
7. Oliver JA and Al-Awqati Q: An endothelial growth factor involved in rat renal development. J Clin Invest 102: 1208-1219, 1998. (Pubitemid 28436281)
8. Everett AD: Identification, cloning, and developmental expression of hepatoma-derived growth factor in the developing rat heart. Dev Dyn 222: 450-458, 2001.
9. Enomoto H, Yoshida K and Kishima Y, et al: Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 36: 1519-1527, 2002. (Pubitemid 35403542)
10. Ren H, Tang X, Lee J, et al: Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 22: 3230-3237, 2004. (Pubitemid 41103677)
11. Yamamoto S, Tomita Y, Hoshida Y, et al: Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 12: 117-122, 2006. (Pubitemid 43166184)
12. Yoshida K, Tomita Y, Okuda Y, et al: Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 13: 159-167, 2006. (Pubitemid 43157409)
13. Uyama H, Tomita Y, Nakamura H, et al: Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 12: 6043-6048, 2006. (Pubitemid 44703767)
14. Zhang A, Long W, Guo Z, et al: Development and clinical evaluation of a multi-purpose mAb and a sandwich ELISA test for hepatoma-derived growth factor in lung cancer patients. J Immunol Methods 355: 61-67, 2010.
15. Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM and Vande Woude GF: Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA 98: 7443-7448, 2001. (Pubitemid 32567968)
16. Zhang J, Ren H, Yuan P, Lang W, Zhang L and Mao L: Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 66: 18-23, 2006. (Pubitemid 43166002)
17. Shi H, Wang J, Dong F, Wang X, Li H and Hou Y: The effect of proteoglycans inhibited by RNA interference on metastatic characters of human salivary adenoid cystic carcinoma. BMC Cancer 9: 456-470, 2009.
18. Matsuki A, Yamamoto S and Nakagami H: No influence of tumor growth by intramuscular injection of hepatocyte growth factor plasmid DNA: safety evaluation of therapeutic angiogenesis gene therapy in mice. Biochem Biophys Res Commun 315: 59-65, 2004. (Pubitemid 38175185)
19. Bernard K, Litman E, Fitzpatrick JL, et al: Functional proteomic analysis of melanoma progression. Cancer Res 63: 6716-6725, 2003. (Pubitemid 37322951)
20. Okuda Y, Nakamura H, Yoshida K, et al: Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 94: 1034-1041, 2003. (Pubitemid 38035516)
21. Yamamoto S, Tomita Y, Hoshida Y, et al: Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 14: 2141-2149, 2007. (Pubitemid 46988256)
22. Everett AD, Stoops T and McNamara CA: Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 276: 37564-37568, 2001.
23. Kishima Y, Yamamoto H, Izumoto Y, et al: Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 277: 10315-10322, 2002. (Pubitemid 34968148)
24. Kishima Y, Yoshida K, Enomoto H, et al: Antisense oligonucleotides of hepatoma-derived growth factor (HDGF) suppress the proliferation of hepatoma cells. Hepatogastroenterology 49: 1639-1644, 2002. (Pubitemid 35277344)
25. Guo Z, He Y, Wang S, Zhang A, Zhao P, Gao C and Cao B: Various effects of hepatoma-derived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells. Oncol Rep 26: 511-517, 2011.
26. Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A and Gera J: mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 67: 11712-11720, 2007.
27. Yoshida K, Nakamura H, Okuda Y, et al: Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J Gastroenterol Hepatol 18: 1293-1301, 2003. (Pubitemid 37464005)
28. Mao J, Xu Z, Fang Y, et al: Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci 99: 2120-2127, 2008.
29. Malecová B and Morris KV: Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs. Curr Opin Mol Ther 12: 214-222, 2010.
30. Desiderio MA: Hepatocyte growth factor in invasive growth of carcinomas. Cell Mol Life Sci 64: 1341-1354, 2007. (Pubitemid 46889234)
31. Gao C and Vande Woude GF: HGF/SF-Met signaling in tumor progression. Cell Res 15: 49-51, 2005. (Pubitemid 41653965)
32. Abounader R and Laterra J: Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7: 436-451, 2005. (Pubitemid 41555616)
33. Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M and Lamszus K: Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 52: 1391-1399, 2003. (Pubitemid 36666954)